drugset / Trial / NCT04654988

Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.

NCT04654988

Phase 4 Recruiting 100 enrolled Medical University of Warsaw
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Myocarditis can result in numerous complications, but there is paucity of data regarding optimal therapy, short- and long-term effects of possibly effective immunosuppressive therapy. The IMPROVE-MC study will provide high-quality scientific data about efficacy and safety of immunosuppressive therapy, non-invasive (MRI, biomarkers) and invasive diagnostics tests (endomyocardial biopsy), and prognosis in myocarditis. The objective of this multicenter, prospective, randomized, double-blind placebo-controlled trial is to assess the efficacy and safety of 12 - month treatment with prednisone and azathioprine comparing to placebo on top of guideline-recommended medical therapy in patients with biopsy-proven virus negative myocarditis or inflammatory cardiomyopathy and reduced ejection fraction (LVEF ≤ 45%). The study will also assess persistence of the treatment effects after 12 months.

Timeline

Start
2022-12-01
Primary completion
2027-09-30
Completion
2028-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azathioprine Small molecule 2 mg/kg
Subject Prednisone Other / unclassified 1 mg/kg